Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tianshuping is a fixed-dose combination pharmaceutical preparation developed by West China Hospital, Sichuan University, specifically for the treatment of essential hypertension. It is a well-known hospital-made preparation (院内制剂) in China. The formulation typically consists of captopril, hydrochlorothiazide, and promethazine hydrochloride. Captopril functions as an angiotensin-converting enzyme (ACE) inhibitor, which lowers blood pressure by reducing peripheral vascular resistance. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water, thereby reducing plasma volume. Promethazine hydrochloride, a first-generation antihistamine with sedative properties, is included in small doses to provide a mild calming effect, which may help manage hypertensive spikes associated with anxiety or stress. This combination leverages multiple physiological pathways to achieve synergistic blood pressure control.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on captopril + hydrochlorothiazide + promethazine.